In this study we investigated the effects of glycine on angiogenesis during embryogenesis, wound healing and tumor growth. In chorioallantoic membrane (CAM) assay, glycine (100 µM) inhibited angiogenesis by more than 50%. We studied dietary glycine's effect on fibrin induced wound healing response in a novel (Fibrin Z-chamber) assay. Fibrin within the chamber triggers the healing cascade leading to formation of granulation tissue (GT) rich in blood vessels and stroma. GT was reduced by more than 30% (p < 0.0001) in dietary Glycine groups as compared to control. We found that microvessel density dropped significantly (15%, p < 0.0003) with dietary glycine whereas the other components of GT were unaffected. We evaluated tumor growth delay utilizing Tumor Z-Chamber (fibrin with R3230 mammary adenocarcinoma cells) since tumors take advantage of angiogenesis and matrix formation. We observed that tumor growth decreased by 15% (p < 0.03) and tumor microvessel density dropped by 20% (p < 0.03) with dietary glycine compared to controls. We found that iNOS protein levels were decreased significantly in both GT (24%-57%) and tumor tissue (19-75%). In conclusion, we found that dietary glycine is a potent anti-angiogenic agent that can reduce wound healing and tumor growth through reduction of iNOS expression.
INTRODUCTION
There is an overwhelming evidence supporting the role of dietary supplements in prevention of certain diseases including cancer. In this study, we investigated the potential of dietary glycine, a non-essential amino acid and an established inhibitory neurotransmitter in the CNS, 1 as an anti-antiangiogenic agent. Recent studies have shown that dietary glycine can induce anti-inflammatory and immunomodulatory effects. 2 The mechanism through which glycine acts involves cell membrane hyperpolarization through activation of Cl channels leading to inhibition of Ca influx. This results in decreased production of oxygen free radicals from inflammatory cells (primarily macrophages) and effectively blunts their function. 3 It is mainly through this mechanism that dietary glycine has been shown to protect against LPS induced endotoxic shock 4 and arthritis, 5 accelerate recovery after alcohol induced liver injury, 6 attenuate CCl4 induced fibrosis, 7 improve survival after liver transplantation 8 and decrease toxicity of certain drugs. 9 Angiogenesis is a complex process through which new blood vessels are formed from the existing vasculature. 10 In adult tissues, angiogenesis occurs concurrently with matrix formation as a part of the host response to injury but is self limited and tightly regulated. 11 When these tight controls are breached, the result is rampant angiogenesis. Impaired regulation of angiogenesis has been implicated in the pathogenesis of variety of conditions including inflammatory diseases (arthritis, inflammatory bowel disease, psoriasis) and most importantly, cancer. 12 Angiogenesis during tumor growth and wound healing response share predominantly the same mechanisms but different regulatory controls. 13, 14 Previous studies have shown that dietary glycine inhibits the growth of B16 melanoma tumors in mice 15 and certain carcinogen induced liver tumors. 16 In these studies glycine inhibited growth of an established tumor in vivo but did not have any cytotoxic effect on tumor cells in vitro. Thus, Rose postulated that glycine's primary effect would be on host tissue but convincing evidence for this hypothesis was not provided. In this study, we have addressed this issue and evaluated how glycine modulates host tissue processes such as angiogenesis and the resultant effect on wound healing and tumor growth.
MATERIAL AND METHODS
Animal Protocols. The Duke Institutional Animal Care and Use Committee approved all animal protocols.
Animal Treatment. Female fisher 344 rats of an average weight of > 150 grams were selected for these studies. The animals were kept in rooms with temperature controlled to 24˚C on a 12 h light-dark cycle. The animals were randomly divided into, control, 5% and 10% dietary glycine groups. Control animals were fed on nitrogen balanced diet without glycine while Glycine (Sigma, MO) was added to the rodent chow of treated groups (5% and 10% w/w). Treated animals were put on glycine diet five days prior to start of experiments and remained on the diet throughout the duration of experiments (12 days).
CAM (Chorioallantoic Membrane) Assay. Fertile chicken eggs were obtained from Melody Hill Ranch, Aptos CA. The eggs were incubated in a standard egg incubator at 37˚C for 3 days. On day 3, eggs were cracked under sterile conditions. The embryos were transferred onto 20¥100 mm sterile plastic petri dishes and allowed to mature at 37˚C in an embryo incubator. On Day 6, three sterile silicon "o" rings were placed on the CAM of each embryo. The rings (15 for each concentration) were loaded with 10 µl of glycine dissolved in water and diluted in 0.5% methylcellulose at concentrations of 10 µM, 100 µM and 1000 µM. Embryos were then returned to the incubator. On Day 8, the images of CAM within the rings were captured with a Zeiss digital imaging system, analyzed and scored for blood vessel density as described elsewhere. 17 A minimum of 27 rings were evaluated for each concentration group in two separate sets of experiments.
Fibrin Z-Chambers (F-ZC). F-ZC is a fibrin gel based in vivo assay to evaluate fibrin induced wound healing response. 18, 19 The Z-chambers were constructed from customized plexiglass rings with internal diameter of 10 mm and having an access port drilled on the side. The two open surfaces were covered by nylon mesh (pore size 180 microns, Millipore, MA) glued to the rings. Fibrinogen (CalBiochem, CA) was prepared in DMEM (Gibco BRL) at a concentration of 4 mg/ml and was converted to fibrin by addition of thrombin (CalBiochem, CA) inside the chambers. It has already been shown that the early angiogenic response to human fibrinogen is very similar to rat fibrinogen in fibrin gel chambers. 20 For the F-ZC experiments Fischer 344 rats were anesthetized with intraperitoneal injections of sodium Phenobarbital (40 mg/kg). The back was shaved and the skin was surgically prepared. Two small, approximately 1.5 cm long midline skin incisions were made in the dorsal region about 3 cm apart in the middle and caudal vertebral regions. Underlying fascia was separated by blunt dissection and small pockets were created lateral to the midline incision to allow subcutaneous implantation of four Z-chambers per animal. The incisions were later closed with surgical clips.
In each experiment 12 animals were used. The animals were divided in three groups of four each (16 chambers each) for control, 5% and 10% dietary glycine. On day 12 post-implantation, the chambers were harvested for analysis. During harvest the nylon mesh covering the F-ZC on both sides (with the granulation tissue in between) was carefully separated from plexiglass ring using a surgical blade. Three chambers were fixed for 24hrs in 10% formalin for paraffin embedding. The fourth chamber from each animal was frozen immediately in liquid nitrogen for later western blot analysis. The experiment was repeated once. To assess the degree of wound healing response, the maximum depth of granulation tissue inside the F-ZC was measured on H&E stained cross sections. Two independent pathologists in a blinded fashion did all measurements. A total of 22 chambers (chambers with distorted tissue omitted) from each group were evaluated for histological analysis and 8 chambers were pooled for western blot analysis.
R3230 Cell Growth and Preparation. R3230 rat mammary cell carcinoma cells for use in Tumor Z-Chambers and colorimetric thiazoyl blue MTT assay were grown in DMEM + 10% FBS + 1% L-Glutamine + 1% penicillin and streptomycin (Gibco BRL). The cells were harvested at 80%-90% confluence by trypsinization with 0.25% trypsin EDTA solution (Sigma).
Colorimetric Thiazoyl Blue (MTT) Assay. The trypsinized R3230 cells were plated in 96-well plates at 2000 cells/well in 190 mL of appropriate medium. Cells were allowed to attach for 24 h, and various doses of glycine in PBS were added to appropriate wells. An equal volume of vehicle used to dissolve glycine was added to control cells. For each concentration, replicates of 4 wells were used. The culture medium was renewed with fresh glycine added every 3 days. After 7 days of culture, the viable cells were measured using MTT reagent. The MTT assay was conducted using the procedure provided by the manufacturer (Promega). Briefly, to each well, 15 L of tetrazolium dye solution was added and incubation of the cells continued for 4 more hours. After 4 h, 100 mL of solubilization/stop solution was added to each well. The plate was kept at room temperature overnight, and the blue color of the product was measured at 575 nm on an ELISA plate reader.
Tumor Z-Chambers (T-ZC). These were prepared and implanted in the same way as Fibrin-ZC. The only difference was addition of R3230 rat mammary carcinoma cells to the final fibrin solution at a concentration of 2 million cells/ml. At this concentration the tumor completely fills the T-ZC in 12 days. 21 Implantation, harvest, sample preservation and evaluation of T-ZC was done in a same way as in F-ZC.
Histology and Immunohistochemistry. Immunohistochemistry was carried out on paraffin embedded tissues. Monoclonal Tissue transglutaminase antibody (TG100, 1:10, endothelial cell marker, non-reactive to Factor XIIIa, unpublished data) (Neomarkers, CA) was used as a blood vessel marker using procedures described previously. 22 Monoclonal ED-1 antibody (Serotec, UK) was used to stain macrophages. Controls for immunohistochemistry were treated with mouse IgG instead of primary antibody and were negative for reactivity. Hematoxylin & Eosin and Masson's Trichrome (MT) was carried out as described elsewhere. 17 MT was used to evaluate collagen (green color) on paraffin embedded tissue sections.
Semi-Quantitative Histological Analysis. Microvessel density (MVD) was calculated as described by Weidner. Briefly, three hot spots or areas with highest visible blood vessels density (marked by the vessel marker) per sample section were selected and the number of blood vessels having a visible lumen was counted for each high power field (HPF, 400X). A total of 15 HPF's (5 sections) were analyzed for each group (control or treatment). The data was then pooled for control and treated tissues to arrive at the mean values for each group.
Collagen was semi-quantitatively estimated on a scale of 0-4. Zero was described as negligible staining, 1 as weak, 2 as moderate, 3 as strong and 4 as complete staining (observed in dermis). Two independent pathologists in a blinded fashion did all measurements.
Macrophage influx into the granulation tissue was assessed on images captured from ED-1 immunostained F-ZC sections. Images of three 400x fields from each section, showing highest density of macrophages were analysed. Macrophages were counted using Zeiss interactive digital imaging software KS 300. A total of 15 images (5 sections) were analyzed for each group (control or treatment).
Western Blot. Western blots were done on tissues obtained from both F-ZC and T-ZC. The chamber contents were pooled for each group (treatment or control). Thus, each blot represented an average response in 8 Z-chambers, 1 each from the total of eight animals within a group over two sets of experiments. Harvested chamber tissues were homogenized in cold lysis buffer (250 µl of lysis buffer was used per chamber, 8 chambers required 2 mls of lysis buffer) containing the proteolytic inhibitor cocktail (Boehringer Mannheim, Germany) followed by sonification. The solutions were then centrifuged, supernatant was removed and protein content was determined using Bio-Rad (Hercules, CA). Gel electrophoresis of the extracted tissue samples (100 µg) for iNOS antigen (iNOS, 1:1000 dilution, R&D systems, MN) was carried as described previously. 22 The amount of protein on the blot was estimated with a densitometer.
Statistics. Unpaired t-test was performed using GraphPad InStat version 3.00 for Windows 95, GraphPad Software, San Diego California USA, www.graphpad.com. All data is shown with ± Standard error of the mean bars. Two tail P-value was used in all cases and a value of < 0.05 was defined as a significant difference between two groups.
RESULTS
Glycine Inhibited Angiogenesis in CAM Assay. The CAM assay was carried out to evaluate the effects of glycine on embryonic angiogenesis. Glycine in methylcellulose solution was administered to the silicon 'o' rings placed on the chorionoallantoic membrane at three different concentrations (10 µM, 100 µM and 1000 µM). The effect of glycine on angiogenic response was assessed in CAM after 48 hrs of incubation. The low dose (10 µM) exhibited a minimal (10% decrease) in vessel density but the difference with controls was not statistically significant. We observed a significant (p = 0.01) 50% reduction in vessel density at the intermediate glycine dose of 100 µM (Fig. 1, 2A and 2B ). This inhibition of angiogenic response did not show any further improvement at the highest dose of 1000 µM (Fig. 1) . These results establish that glycine has anti-angiogenic effects in the CAM assay.
Inhibition of Wound Healing Response in F-ZC. We further investigated the effects of dietary glycine on the ability of tissue to respond to injury. We utilized the F-ZC assay in rats for this purpose. The fibrin within the chamber induces a wound healing response in the host tissues leading to formation of granulation tissue comprising newly formed blood vessels, extracellular matrix and inflammatory cells (primarily macrophages). We quantified the formation of granulation tissue by measuring its thickness inside the F-ZC at day 12 post-implantation.
The depth of granulation tissue that developed inside the chambers of animals on 5% glycine diet, was reduced by 28% (p < 0.0001) as compared to controls (Table 1 ). The reduction further enhanced to 35% (p < 0.0001) with 10% glycine diet as compared to controls (Table 1 , Fig 2C and 2D) .
Decreased Angiogenesis During Wound Healing Response in F-ZC. To characterize the reduction in wound healing response due to dietary glycine, we evaluated all major components of granulation tissue. MVD in granulation tissue was estimated to evaluate endothelial function and we found that it was decreased significantly by more than 18% in both 5% (p = 0.0003) and 10% (p=0.0001) glycine groups as compared to controls (Table 1 , Fig. 2E and 2F ). Collagen estimation was carried out semi quantitatively on Masson's Trichrome stained sections of F-ZC to assess fibroblast activity. We found that even though the amount of granulation tissue was significantly decreased in glycine treated groups there was no quantitative difference on collagen deposition (Table 1) , suggestive of minimal effect on fibroblasts. Macrophages are the key inflammatory cells and play a pivotal role in both angiogenesis and matrix production. We analyzed the F-ZC sections to assess if glycine inhibits macrophage influx into the granulation tissue. Monoclonal ED-1 antibody was used as a marker to identify macrophages within the granulation tissue. No significant difference was found in the number of macrophages infiltrating the granulation tissue in control and treated groups (Table 1) .
Tumor Growth is Inhibited by Reduction of Angiogenic Response in T-ZC. Before initiating the in vivo tumor studies to assess if the anti angiogenic effects of glycine results in inhibition of tumor growth, we carried out in vitro experiment to assess whether glycine inhibits R3230 tumor cell proliferation. Glycine had no effect on R3230 cell growth at concentrations ranging from 0.004 µM to 4000 µM (data not shown).
R3230 tumor cells were allowed to grow and form a tumor in T-ZC as described in methods. By day 12 post implantation tumor tissue completely filled control T-ZC. The thickness of tumor tissue was reduced by 13% in both 5% (p = 0.05) and 10% (p = 0.03) glycine groups as compared to the controls (Table 1 , Fig. 2G and 2H) . MVD in tumor tissue was 20% lower with both 5% (p = 0.001) and 10% (p = 0.03) glycine diet as compared to controls (Table 1) , a result consistent with the findings in wound healing experiment in F-ZC.
Inhibition of Inducible Nitric Oxide Synthase (iNOS) Expression in Granulation and Tumor Tissue. We further probed the ability of macrophage to function, since it is known that glycine blunts macrophage activity. We decided to measure iNOS protein, which serves as a marker of macrophage activity, 24 in both granulation and tumor tissue lysates. Western blots were run on both granulation and tumor tissue lysates using a monoclonal iNOS antibody (Fig. 3A) . We found that iNOS expression in granulation tissue decreased by 24% and 57% in 5% and 10% glycine treated groups respectively as compared to controls (Table 1, Fig. 3B ). We observed similar reduction in iNOS protein expression (19% and 75% decrease in 5% and 10% glycine treated groups respectively) in tumor tissue (Table 1, Fig. 3B ). These results indicate that at higher levels of dietary glycine macrophage function was inhibited.
DISCUSSION
Dietary supplements are known to play a significant role in prevention of chronic diseases and cancer. Some of these agents have been shown to exert their protective effect specifically by inhibiting angiogenesis. For instance α-tocopherol has been shown to inhibit prostate carcinogenesis by reducing vascular endothelial growth factor (VEGF) levels, a key pro-angiognenic cytokine. 25 Omega-3 fatty acids reduced tumor growth of the breast cancer cell line MDA-MB 231 by decreasing the microvessel density. 26 In another study catechins and polyphenols from plant extracts such as green tea have shown to exert anti cancer activity by inhibiting angiogenesis. 27 The results of these studies suggest that angiogenesis is a key pathway inhibited by a number of dietary agents to exert their beneficial effects against disease processes particularly cancer. We wished to investigate whether glycine's known anti-inflammatory and postulated anti-tumor activity is modulated through regulating host inflammatory response and angiogenesis.
We have shown for the first time that glycine, a non-essential amino, acid is a potent anti-angiogenic agent. We investigated the effects of glycine during the three events where the process of angiogenesis is critical i.e., embryogenesis, wound healing and tumor growth. During embryogenesis, two processes contribute to development of vasculature i.e., vasculogenesis (de novo development of blood vessels) and angiogenesis. 28 We showed in an established model of embryonic angiogenesis (CAM assay) that glycine inhibited blood vessel growth. Since the embryo during early development is incapable of mounting an immune or inflammatory response, 29, 30 it is conceivable that glycine exerted direct inhibitory effects on mesenchymal/ early endothelial cells.
The response to tissue injury as studied in F-ZC provides a more direct opportunity to study angiogenesis in adult tissues. We observed that glycine reduced the formation of granulation tissue during wound healing response. We quantified the three major components comprising granulation tissue i.e blood vessels, matrix deposition, and influx of inflammatory cells. The only significant decrease was observed in the microvessel density count of granulation tissue treated with glycine, suggesting that glycine exerted an inhibitory effect on endothelial cells in vivo. This result is consistent with the finding of Rose where they observed glycine exerted anti-proliferative effects on endothelial cells in vitro. 15 iNOS, an inducible form of nitric oxide synthase (NOS), has not only been shown to serve as marker of macrophage activity but is also essential for process of wound healing. 31, 32 Shi reported decreased wound healing response by reduced epithelialisation and wound contraction in iNOS knock out mice. 33 Thornten observed enhanced wound breaking strength, collagen synthesis, epithelialisation and wound contraction following direct transfection of iNOS gene in cutaneous wounds. 34 Yamasaki noted reversal of impaired wound repair in iNOS -deficient mice by topical adenoviral mediated iNOS gene transfer. Macrophages are known to be the major source of iNOS production during wound healing and their expression of iNOS is highest at the granulation tissue phase. 35 Macrophages have been implicated in all aspects of wound healing and angiogenesis. 36 During the granulation tissue phase, they are the predominant cell type and are responsible for production of cytokines and growth factors essential to the healing cascade. Wheeler has shown that dietary glycine inhibited tissue macrophages resulting in decreased production of cytokines particularly tumor necrosis factor (TNF-α). 2, 37 We investigated the influx of macrophages in the mature granulation tissue and found no difference in macrophage density. This was a significant finding since the tremendous decrease in iNOS protein expression in granulation tissue of F-ZC's could not be attributed to decreased number of macrophages per unit area. This finding was suggestive of glycine's inhibition of macrophage function through reduction of iNOS expression. It can be summarized that reduction in iNOS activity of macrophages is one of the possible mechanisms responsible for inhibition of wound healing response.
Tumors require new blood vessel (nutrition) and matrix (scaffold) for growth, the same processes employed in response to tissue injury during wound healing. 12, 18 Inhibition of angiogenesis by glycine has been implicated in growth delay of certain tumors. We observed that dietary glycine inhibited R3230 mammary tumor in T-ZC. This was associated with significant decrease in blood vessel formation. We confirmed that glycine had no direct cytotoxic or growth inhibitory effects on the R3230 rat mammary adenocarcinoma cells in vitro. We found an association of decreased iNOS protein expression to tumor growth delay, a trend similar to the one observed in wound healing experiments.
There is an overwhelming amount of clinical and experimental evidence supporting a positive association between nitric oxide (NO) production and tumor progression. In vivo studies have shown increased growth rate, vascular density and invasiveness of a human cancer cell lines transfected to constitutively express iNOS. 38 Conversly inhibition of iNOS by N-Nitro-L-Arginine Methyl ester inhibits tumor-induced angiogenesis in Mammary tumors. 30 Other studies have shown that up-regulation of iNOS is associated with increased vascular density and enhanced biological aggressiveness of breast cancer. 39, 40 The issue of which cell types are responsible for iNOS production in tumor tissues is more complex. In rodent mammary tumor tissue, Jang suggested higher levels of iNOS emanate from tumor and stromal cells. 41 We have observed earlier that advancing margins of R3230 mammary adenocarcinoma tumors are rich in macrophages, 42 another important source of iNOS as discussed earlier. Tumor vasculature associated with the rat mammary carcinoma R3230 tumor has been shown to constitutively express high levels of iNOS. Our observance of tumor iNOS inhibition in dietary glycine treated tumor tissues is consistent with the wound healing study and is suggestive of a novel relationship between glycine and iNOS regulatory pathways. This regulatory pathway between glycine and iNOS may be effective in multiple cell types in tumors considering macrophages are not the predominant cell type producing iNOS as in the case of the healing tissue.
In conclusion, we have shown that glycine inhibits angiogenesis during embryogenesis, wound healing and tumor growth. We found a potential relationship between glycine and iNOS and its association with inhibition of angiogenesis. 
